A nomogram combining plasma fibrinogen and systemic immune‑inflammation index predicts survival in patients with resectable gastric cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 05 2021
13 05 2021
Historique:
received:
21
10
2020
accepted:
29
04
2021
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
9
11
2021
Statut:
epublish
Résumé
Hyperfibrinogenemia and cancer-associated systemic inflammatory response are strongly associated with cancer progression and prognosis. We aimed to develop a novel prognostic score (F-SII score) on the basis of preoperative fibrinogen (F) and systemic immunoinflammatory index (SII), and evaluate its predictive value in patients with resectable gastric cancer (GC). Patients diagnosed with GC between January 2012 and December 2016 were reviewed. The F-SII score was 2 for patients with a high fibrinogen level (≥ 3.37 g/L) and a high SII (≥ 372.8), whereas that for patients with one or neither was 1 or 0, respectively. A high F-SII score was significantly associated with older patient age, a high ASA score, large tumor size, large proportion of perineural invasion, and late TNM stage. Multivariate analysis indicated that the F-SII score, histological grade, and TNM stage were independent factors for overall survival (OS). The Harrell's concordance index (C-index) of a nomogram based on the F-SII score and several clinicopathological manifestations was 0.72, which showed a better predictive ability for OS than the TNM stage alone (0.68). In conclusion, preoperative F-SII may serve as a useful predictive factor for OS and refine outcome prediction for patients with resectable GC combined with traditional clinicopathological analysis.
Identifiants
pubmed: 33986408
doi: 10.1038/s41598-021-89648-9
pii: 10.1038/s41598-021-89648-9
pmc: PMC8119703
doi:
Substances chimiques
Fibrinogen
9001-32-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10301Références
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
Gastric Cancer. 2019 May;22(3):536-545
pubmed: 30377862
Oncol Lett. 2016 Feb;11(2):1537-1544
pubmed: 26893776
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Lancet. 2012 Jan 28;379(9813):315-21
pubmed: 22226517
Chin J Cancer. 2017 Sep 12;36(1):75
pubmed: 28899420
Lancet Gastroenterol Hepatol. 2018 Jul;3(7):460-468
pubmed: 29709558
Jpn J Clin Oncol. 1998 Dec;28(12):740-4
pubmed: 9879291
Int J Mol Sci. 2017 Mar 29;18(4):
pubmed: 28353661
Ann Surg. 2017 Mar;265(3):539-546
pubmed: 27070934
Br J Cancer. 2018 Mar 20;118(6):831-838
pubmed: 29485980
Ann Surg. 2019 Jul;270(1):139-146
pubmed: 29334554
Jpn J Clin Oncol. 2005 Oct;35(10):595-600
pubmed: 16186176
J Thromb Haemost. 2008 Jan;6(1):176-83
pubmed: 17949478
Semin Urol Oncol. 2002 May;20(2):79-81
pubmed: 12030248
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Tohoku J Exp Med. 2015;236(4):297-304
pubmed: 26250537
Ann Surg Oncol. 2015 Dec;22(13):4363-70
pubmed: 25805235
J Cancer. 2019 Oct 17;10(25):6244-6251
pubmed: 31772657
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Blood. 2000 Dec 1;96(12):3772-8
pubmed: 11090059
Br J Surg. 2017 Mar;104(4):401-407
pubmed: 28072456
World J Surg. 2016 Aug;40(8):1904-9
pubmed: 26969673
BMC Cancer. 2006 Jun 01;6:147
pubmed: 16740157